Immix Biopharma doses first two patients in Phase 1b/2a combination trial

Immix Biopharma announced dosing of the first 2 patients in its IMX-110 + Beigene/Novartis anti-PD-1 Tislelizumab Combination Phase 1b/2a Clinical Trial in patients with advanced solid tumors. Initial clinical data from this combination trial is anticipated to be released on a rolling basis beginning in 1H 2023. IMX-110 + Beigene/Novartis anti-PD-1 tislelizumab combination treatment is designed to enhance response to solid tumors by turning immunologically "cold" tumors "hot". In ImmixBio prior IMX-110 + anti-PD-1 preclinical experiments, a 50% improvement was produced by IMX-110 + anti-PD-1 in a genetic pancreatic cancer mouse model in which mice develop their own pancreatic cancer and have an intact immune system, compared to a 4-drug combination of 2 chemotherapies and 2 immunotherapies in the same genetic pancreatic cancer mouse model.